US Executive Compensation Proxy SEC Filings — May 28, 2026

Executive Compensation Insights

By Gunpowder Editorial ·

9 high priority 9 total filings analysed

Executive Summary

This batch of 9 DEF 14A filings reveals a mixed governance landscape dominated by a transformative energy merger at Devon Energy (with Coterra), a high-stakes SPAC survival vote at Lionheart Holdings, and numerous routine annual meetings. A key period-over-period theme emerges from Devon's disclosed operational outperformance: oil volumes exceeded top-end guidance and capital efficiency improved materially, suggesting strong execution.

Insider activity is sparse across the filings, but Lionheart's insiders (25% ownership) are voting to extend the business combination deadline, signaling commitment but also highlighting liquidation risk. Forward-looking data is most potent at Devon ($2B in total synergy targets by 2027) and Lionheart (extension deadline decision). Sector themes center on SPAC extension urgency, executive pay advisory votes at several small-caps (Educational Development, ChargePoint, Willamette Valley), and a shareholder proposal at Neuberger Berman NBXG. Capital allocation insights are limited, as most filings are governance-focused without detailed balance sheet or buyback data. The most actionable intelligence revolves around Devon's post-merger synergy capture and Lionheart's make-or-break shareholder vote on June 20, 2026.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: DEF 14A

Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from May 27, 2026.

Investment Signals (8)

  • Devon Energy (DVN) (BULLISH)

    Production outperformed with oil volumes surpassing top-end guidance; capital efficiency exceeded industry averages. Merger with Coterra targets $1B sustainable pre-tax synergies by end-2027 plus $1B in free cash flow improvements from prior optimization. Delaware Basin asset will drive >50% of production.

  • Insiders holding 25% of shares committed to vote FOR extension to March 2027, indicating strong conviction to complete a deal. $230M trust with $6M private placement warrants provides deal firepower. [BULLISH for risk-tolerant SPAC investors]

  • Cellectar Biosciences (CLRB)

    Board recommending 2M share increase in stock incentive plan (currently outstanding: 7.99M shares) — a 25% dilution signal that aligns management incentives with long-term value creation, typical for pre-revenue biotech. [BULLISH for growth narrative]

  • Proposing multiple governance upgrades (eliminate plurality voting, remove 'for cause' removal restriction, opt out of DGCL Section 203, officer exculpation) — signals institutional investor-friendly reforms. 102.6M shares outstanding with no preferred stock overhang.

  • Crimson Wine Group (CWGL)

    20.6M shares outstanding; clean governance with no contested items. Low materiality filing but steady structure supports passive holders. [NEUTRAL/BULLISH]

  • Educational Development (EDUC) (NEUTRAL)

    Cumulative voting authorized — provides minority shareholder protection. Board temporarily set at 5 directors. Low-float stock (8.5M shares) could see volatility around July 8 AGM if dissident activity emerges.

  • Willamette Valley Vineyards (WVVI)

    New CEO Michael Osborn (former Wine.com founder/EV) appointed May 2025 — first report since transition. Founder James Bernau remains Chairperson. No family relationships among directors — governance positive. [BULLISH for turnaround thesis]

  • ChargePoint Holdings (CHPT)

    EV charging sector proxy with advisory vote on exec comp. Virtual-only meeting structure suggests cost discipline. Fiscal year ended Jan 31, 2026 — upcoming earnings will provide YoY revenue trends. [NEUTRAL, sector-specific]

Risk Flags (7)

  • If shareholders do not approve extension beyond June 20, 2026, company must liquidate trust ($230M) — 100% capital loss for SPAC holders who do not redeem. Outcome dependent on public shareholder support

  • Despite $230M trust, no target identified yet. Nine months since IPO (closed June 2024) with only ~12 months to deadline — typical SPAC failure risk if no deal materializes

  • Cellectar Biosciences — Dilution Risk [HIGH RISK]

    Seeking approval to increase shares under stock plan by 2M (25% of current outstanding 7.99M) and warrant exercise for 39.6M shares — massive potential dilution of ~500% if warrants are exercised. Pre-revenue biotech with no disclosed financial results

  • Willamette Valley Vineyards — Concentrated Control [MEDIUM RISK]

    Founder James Bernau has served as President and Chairperson since 1988 — founder-led company with staggered board, reducing accountability. New CEO only appointed May 2025, limited track record

  • Educational Development — Low Liquidity [MEDIUM RISK]

    Only 8.5M shares outstanding. Cumulative voting could lead to slow or contentious board elections if activist shareholders engage. No disclosed insider trading activity or forward guidance

  • Neuberger Berman NBXG — Shareholder Proposal [LOW RISK]

    Proxy includes a non-binding stockholder proposal specific to NBXG — nature not detailed but signals some shareholder dissatisfaction. Closed-end fund with no financial performance data disclosed

  • SBC Medical Group Holdings — Virtual Meeting Only [LOW RISK]

    Virtual-only meeting on July 9 JST (July 8 ET) limits shareholder engagement. Multiple complex charter amendments (5 proposals) could confuse retail investors

Opportunities (6)

  • Devon Energy — Synergy Capture Play (OPPORTUNITY)

    With $2B total pre-tax synergy target by end-2027 ($1B merger + $1B prior optimization), DVN trades at compelling valuation. Delaware Basin >50% production means high-margin, low-decline asset base. Production already beating guidance — upgrade potential on Q2 results.

  • With insiders holding 25% and voting FOR, the key unknown is public shareholder behavior. Trust value ~$10/share if extension fails — but if it passes, potential to trade above trust as deal speculation builds. High-risk/high-reward event play before June 20.

  • Cellectar Biosciences — Biotech Catalyst Calendar (OPPORTUNITY)

    AGM July 7, 2026. Share increase for incentive plan signals potential hiring or retention of key talent. Pre-revenue stage with 7.99M shares — any positive clinical data could cause significant upside. Monitor SEC filings for 8-Ks post-AGM.

  • ChargePoint Holdings — EV Sector Reentry Point (OPPORTUNITY)

    Virtual AGM July 21, 2026. EV charging sector has corrected significantly since 2021 highs. If FY2026 (Jan 31) results show improving unit economics or revenue acceleration, CHPT could re-rate. Watch for guidance commentary in proxy disclosures.

  • Willamette Valley Vineyards — New CEO Catalyst (OPPORTUNITY)

    Michael Osborn's background at Wine.com brings DTC and digital expertise to a traditional winery. If operational improvements materialize, this micro-cap ($WVI) could see earnings lift. Next earnings report will be key proving ground.

  • SBC Medical Group Holdings — Governance Upgrade Story (OPPORTUNITY)

    Moving to majority voting and opting out of DGCL 203 (anti-takeover) signals management is aligning with best practices. With 102.6M shares and clean structure, could attract institutional interest. July 9 AGM vote is catalyst.

Sector Themes (5)

  • SPAC Extension Deadlines Under Pressure

    Lionheart Holdings joins a growing list of SPACs seeking shareholder approval to extend deadlines (June 20 vote). With $230M in trust and 25% insider support, success is not guaranteed. The outcome will set precedent for other SPACs needing extensions in H2 2026.

  • Proxy Season Governance Reforms

    Multiple companies (SBC Medical, Educational Development, Cellectar) are proposing governance changes — eliminating plurality voting, removing staggered board provisions, officer exculpation. This reflects post-2023 SEC rule enforcement and institutional pressure for board accountability.

  • Energy Sector Consolidation Delivering Synergies

    Devon Energy's merger with Coterra exemplifies the ongoing E&P consolidation theme. The combined $2B synergy target (~$1B from merger + $1B from prior optimization) and Delaware Basin focus mirror broader sector trends (Exxon/Pioneer, Chevron/Hess). Expect more deals as scale drives efficiency.

  • Small-Cap Shareholder Engagement via Virtual Meetings

    All 9 filings either mandate or default to virtual or webcast-only annual meetings. While cost-effective, this limits retail shareholder engagement and could reduce dissent voting. Watch for investor pushback in future proxy seasons.

  • Biotech Dilution vs Incentive Alignment

    Cellectar's 2M share increase proposal (25% dilution) reflects the perennial biotech tension — needing equity to attract talent while managing shareholder dilution. Pre-revenue biotechs with warrant overhang (39.6M warrants) require careful NAV analysis before investing.

Watch List (7)

  • Extraordinary general meeting to approve extension to March 2027. If not approved, trust liquidation before June 20, 2026. Watch for proxy advisory firm recommendations (ISS/Glass Lewis) — they will sway public shareholder votes. [DEADLINE: June 20, 2026]

  • Devon Energy — Post-Merger Operational Update
    👁

    Q2 2026 earnings will be first report with Coterra assets fully integrated. Watch for synergy realization timeline, production updates, and capital allocation (buybacks vs debt reduction). [ESTIMATED: August 2026]

  • ChargePoint Holdings — FY2026 Annual Results (ONGOING)
    👁

    Form 10-K for FY ended Jan 31, 2026 should be filed by April 30, 2026 (already past). If not yet public, watch for delayed filing risk. AGM July 21 provides management commentary.

  • Cellectar Biosciences — Shareholder Vote on Warrants
    👁

    Exercise of up to 39.6M warrants (5x current shares) could close at AGM July 7. If approved, massive dilution but also cash infusion for clinical programs. Watch 8-K post-vote. [DATE: July 7, 2026]

  • Willamette Valley Vineyards — New CEO Performance
    👁

    First full year under CEO Michael Osborn (appointed May 2025). FY2026 annual report (likely due Q2 2026) will show initial impact of operational changes. Pre-announcement risk in coming weeks. [ESTIMATED: May-June 2026]

  • Neuberger Berman NBXG — Shareholder Proposal Outcome
    👁

    Non-binding proposal at August 6 joint annual meeting. While non-binding, significant support could pressure board for action. Watch for pre-meeting activist filings. [DATE: August 6, 2026]

  • Educational Development — Low Float Trading Activity
    👁

    Only 8.5M shares outstanding. Any insider buying/selling post-AGM (July 8) would be significant given low liquidity. Monitor Form 4 filings. [DATE: July 8 AGM + ongoing]

Filing Analyses (9)
DEVON ENERGY CORP/DE DEF 14A positive materiality 8/10

28-05-2026

Devon Energy's 2026 Proxy Statement details the transformational merger with Coterra, creating a company with greater scale and a world-class Delaware Basin asset. The combined entity expects to capture $1 billion in sustainable pre-tax synergies by the end of 2027, on top of $1 billion in annual pre-tax free cash flow improvements from a prior optimization program. The Board recommends voting FOR all director nominees, ratification of KPMG as auditor, and approval of executive compensation.

  • · The Delaware Basin asset is expected to generate more than half of total production and cash flow, backed by over a decade of top-tier drilling inventory.
  • · The merger enhances geographic diversity and capital allocation optimization through commodity cycles.
  • · In 2025, Devon's production outperformed expectations, with oil volumes surpassing the top end of guidance; capital efficiency significantly improved and exceeded industry averages.
  • · The record date for the annual meeting is May 18, 2026, and the meeting will be held virtually on June 30, 2026.
  • · The Board consists of 11 directors: 6 from legacy Devon and 5 from legacy Coterra.
SBC Medical Group Holdings Inc DEF 14A neutral materiality 5/10

28-05-2026

SBC Medical Group Holdings Inc filed a DEF 14A proxy statement on May 28, 2026, soliciting proxies for its virtual 2026 annual meeting of stockholders to be held on July 9, 2026 (JST). The board recommends voting FOR seven proposals, including the election of director nominees, ratification of MaloneBailey, LLP as auditor for FY2026, and several charter amendments (eliminating plurality voting for directors, removing 'for cause' removal restriction, opting out of DGCL Section 203, providing officer exculpation, and other technical amendments). The record date is May 20, 2026, with 102,576,943 shares of common stock outstanding (net of 270,000 shares held by a wholly-owned subsidiary).

  • · Annual meeting will be held virtually on Thursday, July 9, 2026 at 9:00 a.m. JST (8:00 p.m. ET on July 8, 2026).
  • · Record date for voting is May 20, 2026.
  • · Board recommends voting FOR: (1) election of director nominees; (2) ratification of MaloneBailey, LLP as independent auditor for fiscal year ending December 31, 2026; (3) amendment to eliminate plurality voting for directors; (4) amendment to eliminate 'for cause' removal restriction; (5) amendment to opt out of DGCL Section 203; (6) amendment to provide officer exculpation; (7) other technical charter amendments.
  • · Shares held in street name will only be voted by brokers without instructions on Proposal 2 (auditor ratification) — not on other proposals.
EDUCATIONAL DEVELOPMENT CORP DEF 14A neutral materiality 5/10

28-05-2026

Educational Development Corporation filed its definitive proxy statement (DEF 14A) on May 28, 2026, for the 2026 Annual Meeting of Shareholders scheduled for July 8, 2026. The meeting will include the election of two Class I directors (Bradley V. Stoots and Steven G. Hooser), ratification of HoganTaylor LLP as independent auditor for FY ending February 28, 2027, and an advisory vote on executive compensation. As of the record date of May 19, 2026, there were 8,511,364 shares of common stock outstanding.

  • · The Board of Directors has temporarily set the number of directors at five.
  • · Class I directors serve a three-year term expiring at the 2029 annual meeting.
  • · Cumulative voting is authorized for the election of directors.
  • · A majority of outstanding shares is required for a quorum.
  • · Abstentions count as present for quorum but have no effect on director elections; however, for auditor ratification, abstentions have the same effect as votes against.
  • · The company uses the SEC's Notice and Access model to reduce mailing costs and environmental impact.
  • · Proxy materials are available at www.edcpub.com.
  • · The annual report for FY ended February 28, 2026, is available online.
Crimson Wine Group, Ltd DEF 14A neutral materiality 3/10

28-05-2026

Crimson Wine Group, Ltd. filed its definitive proxy statement (DEF 14A) on May 28, 2026, for the annual meeting of stockholders to be held virtually on July 23, 2026. The meeting will include the election of seven directors and ratification of BPM LLP as the independent auditor for fiscal year 2026. As of the record date of May 26, 2026, there were 20,586,027 shares of common stock outstanding and entitled to vote.

  • · Annual meeting will be held virtually on July 23, 2026 at 10:00 a.m. Pacific Time.
  • · Record date for voting is May 26, 2026.
  • · Proposal 1: Election of seven directors (plurality vote required).
  • · Proposal 2: Ratification of BPM LLP as independent auditor for year ending December 31, 2026 (majority vote required).
  • · Proxy materials were first mailed on or around June 9, 2026.
  • · Virtual meeting password: crimson2026 (case-sensitive).
Neuberger Berman Next Generation Connectivity Fund Inc. DEF 14A neutral materiality 4/10

28-05-2026

Neuberger Berman Next Generation Connectivity Fund Inc. (NBXG) filed a definitive proxy statement (DEF 14A) on May 28, 2026, for a joint annual meeting of stockholders to be held on August 6, 2026. The meeting will include the election of three Class III Directors (Tom D. Seip, Franklyn E. Smith, and Joseph V. Amato) and a non-binding stockholder proposal specific to NBXG. The filing does not contain any financial results or performance data, so no positive or negative financial metrics are available to report.

  • · The record date for voting is May 15, 2026.
  • · The proxy statement will be mailed to stockholders on or about May 28, 2026.
  • · NBXG has no preferred stock outstanding.
  • · The Board has a retirement policy generally requiring directors to retire by the end of the year they turn 77.
  • · The Board has previously approved discount mitigation measures including tender option programs and fund mergers.
ChargePoint Holdings, Inc. DEF 14A neutral materiality 5/10

28-05-2026

ChargePoint Holdings, Inc. filed its definitive proxy statement (DEF 14A) on May 28, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on July 21, 2026. The Board recommends voting FOR the election of three Class III director nominees, FOR ratification of the independent registered public accounting firm, and FOR the advisory vote on named executive officer compensation. The filing includes detailed executive compensation disclosures, director compensation, and governance information for fiscal year ended January 31, 2026.

  • · Annual Meeting to be held virtually on Tuesday, July 21, 2026 at 11:00 a.m. Pacific Time via www.virtualshareholdermeeting.com/CHPT2026
  • · Record date for voting is May 26, 2026
  • · Proxy materials made available on or about May 28, 2026
  • · Stockholders can vote via Internet (www.proxyvote.com), telephone (1-800-690-6903), or mail by 11:59 p.m. Eastern Time on July 20, 2026
  • · Three proposals: Election of Class III directors (Proposal 1), Ratification of independent auditor (Proposal 2), Advisory vote on executive compensation (Proposal 3)
  • · Board unanimously recommends FOR all three proposals
  • · Business Combination with Switchback closed on February 26, 2021
Cellectar Biosciences, Inc. DEF 14A neutral materiality 5/10

28-05-2026

Cellectar Biosciences filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting to be held on July 7, 2026. The meeting will include votes on electing two Class III directors, increasing shares under the 2021 Stock Incentive Plan by 2,000,000 shares, ratifying Deloitte as auditor, an advisory vote on executive compensation, and approving the exercise of warrants for up to 39,618,078 shares. The record date is May 19, 2026, with 7,991,812 shares outstanding.

  • · The annual meeting will be held virtually on July 7, 2026 at 10:00 AM local time.
  • · Stockholders of record as of May 19, 2026 are entitled to vote.
  • · The board recommends voting FOR all proposals.
  • · Proposal 5 seeks approval to exercise warrants for up to 39,618,078 shares of common stock.
  • · Proposal 6 is an adjournment proposal to solicit additional proxies if needed for Proposal 5.
Lionheart Holdings DEF 14A mixed materiality 8/10

28-05-2026

Lionheart Holdings is seeking shareholder approval to extend its deadline to complete a business combination from June 20, 2026 to March 20, 2027, and to adjourn the extraordinary general meeting if needed. The company raised $230M in its IPO and has $230M held in trust, but faces liquidation if the extension is not approved. Insiders, holding 25% of shares, will vote in favor, but the outcome depends on public shareholder support.

  • · The company is a blank check company incorporated in the Cayman Islands on February 21, 2024.
  • · The IPO closed on June 20, 2024, with 23,000,000 units sold at $10.00 per unit, including full exercise of the underwriters' over-allotment option.
  • · Simultaneously with the IPO, 6,000,000 private placement warrants were sold at $1.00 each, generating $6M in gross proceeds.
  • · The Trust Account holds $230M ($10.00 per unit) from the IPO and private placement proceeds.
  • · If the extension is not approved, the company will redeem public shares at the per-share amount in the Trust Account (net of taxes and up to $100K for dissolution expenses) and then liquidate.
  • · The extension would move the deadline from June 20, 2026 to March 20, 2027 (nine months).
  • · Insiders (Sponsor, directors, officers) hold 7,666,667 Class B ordinary shares, representing 25% of outstanding shares, and are expected to vote in favor of both proposals.
  • · Insiders are not entitled to redeem their shares.
  • · The Sponsor may purchase public shares or warrants in the open market or privately, potentially including agreements to vote in favor or not redeem.
  • · No business combination is being voted on at this meeting.
WILLAMETTE VALLEY VINEYARDS INC DEF 14A neutral materiality 5/10

28-05-2026

Willamette Valley Vineyards, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Shareholders to be held on July 11, 2026. The meeting will be conducted via online live audio webcast, with shareholders voting on the election of two directors, ratification of Baker Tilly US, LLP as independent auditor for 2026, and a non-binding advisory vote on executive compensation. The record date is May 8, 2026, with 4,979,529 shares outstanding held by 1,745 registered holders. The proxy statement notes that executive officers and directors have no interest in Proposals 2 or 3, and that there are no family relationships among current directors or executive officers.

  • · The Board is divided into three groups (I, II, III) with staggered three-year terms.
  • · James W. Bernau founded the company in 1988 and has served as President and Chairperson since inception.
  • · Michael Osborn was appointed CEO in May 2025, previously serving as founder and EVP of Wine.com.
  • · John Ferry has been CFO since September 2019.
  • · There are no family relationships among current directors or executive officers.
  • · Proxies marked as abstaining will not affect voting results; broker non-votes are permitted only for Proposal 2 (ratification of auditor).
  • · Shareholders may revoke proxies until 5:00 p.m. Eastern time on July 10, 2026.

Get daily alerts with 8 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 9 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Executive Compensation Proxy SEC Filings

🇺🇸 More from United States

View all →